OnCo
Cancers & treatments·Regimen libraryFirst line

mFOLFOX6

Checked 2026-09-09

Adjuvant stage III colon (6 months) or metastatic colorectal and upper GI first line

Also called FOLFOX.

One cycle

every 14 days × 12 · about 24 weeks in total
1234567891011121314Oxaliplatin: 85 mg/m², IntravenousOxaliplatinLeucovorin (folinic acid): 400 mg/m², IntravenousLeucovorin (folinic aci…Fluorouracil bolus: 400 mg/m², IntravenousFluorouracil bolusFluorouracil infusion: 2,400 mg/m², IntravenousFluorouracil infusion
14-day cycle × 12 (6 months adjuvant); until progression metastatic (about 24 weeks)Intravenous Continuous infusion

Components

DrugDoseRouteDays
Oxaliplatin
Third-generation platinum (DACH-platinum)
85 mg/m²IVD1
Leucovorin (folinic acid)
400 mg/m²IVD1
Fluorouracil bolus
Fluoropyrimidine antimetabolite
400 mg/m²IVD1
Fluorouracil infusion
Fluoropyrimidine antimetabolite
2,400 mg/m²IVD1, 2 (46 h infusion)
Cycles
12 (6 months adjuvant); until progression metastatic
14-day cycle
Emetogenicity
Moderate (30-90%)
G-CSF
Not routine

Notes

  • Oxaliplatin neuropathy is cumulative; IDEA showed 3 months of CAPOX is non-inferior for low-risk stage III (T1-3 N1).
  • Bevacizumab 5 mg/kg or an anti-EGFR antibody is added on day 1 in metastatic disease by RAS/BRAF status and sidedness.

Used in

Colorectal cancerGastric & gastro-oesophageal junction cancerOesophageal cancerPancreatic ductal adenocarcinoma
Trials
PARADIGMSUNLIGHT
Products
FOLFOX (5-FU, leucovorin, oxaliplatin)OxaliplatinFluorouracil (5-FU)

Source

MOSAIC, NEJM 2004 (FOLFOX4); mFOLFOX6 per NCCN Colon Cancer

Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.

Other regimens for these cancers

CAPOX
Adjuvant stage III colon (3 or 6 months), rectal total neoadjuvant therapy, metastatic first line
every 21 days × 4
FOLFIRI
Metastatic colorectal first or second line (with bevacizumab, aflibercept, ramucirumab or an anti-EGFR antibody)
every 14 days
FOLFIRINOX
Metastatic pancreatic cancer, performance status 0-1
every 14 days × 12
mFOLFIRINOX (adjuvant)
Resected pancreatic cancer, fit patients, started within 12 weeks of surgery
every 14 days × 12
Gemcitabine + nab-paclitaxel
Metastatic pancreatic cancer first line; adjuvant option when FOLFIRINOX is not tolerated
every 28 days
Gemcitabine monotherapy
Frail patients or adjuvant when combinations are not tolerated
every 28 days × 6
NALIRIFOX
Metastatic pancreatic cancer first line
every 14 days
FLOT
Resectable gastric or gastro-oesophageal junction adenocarcinoma, cT2 or higher or node-positive
every 14 days × 4
All regimensCAPOX →